QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.066753v1 310/3/952    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cryan, J. F. Articles by Spooren, W. P. J. M. Search for Related Content PubMed PubMed Citation Articles by Cryan, J. F. Articles by Spooren, W. P. J. M.

BEHAVIORAL PHARMACOLOGY

Behavioral Characterization of the Novel GABA_B Receptor-Positive Modulator GS39783 (N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): Anxiolytic-Like Activity without Side Effects Associated with Baclofen or Benzodiazepines

Neuroscience Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland

The role of GABA_B receptors in various behavioral processes has been largely defined using the prototypical GABA_B receptor agonist baclofen. However, baclofen induces sedation, hypothermia and muscle relaxation, which may interfere with its use in behavioral paradigms. Although there is much evidence for a role of the inhibitory neurotransmitter GABA in the pathophysiology of anxiety, the role of GABA_B receptors in these disorders is largely unclear. We recently identified GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine) as a selective allosteric positive modulator at GABA_B receptors. The aim of the present study was to broadly characterize the effects of GS39783 in well-validated rodent models for motor activity, cognition, and anxiety. The following tests were included: locomotor activity in rats and mice, rotarod and traction tests (including determinations of core temperature) in mice, passive avoidance in mice and rats, elevated plus maze in rats, elevated zero maze in mice and rats, stress-induced hyperthermia in mice, and pentobarbital- and ethanol-induced sleep in mice. Unlike baclofen and/or the benzodiazepine chlordiazepoxide, GS39783 had no effect in any of the tests for locomotion, cognition, temperature, or narcosis. Most interestingly, GS39783 had anxiolytic-like effects in all the tests used. Overall, the data obtained here suggest that positive modulation of GABA_B receptors may serve as a novel therapeutic strategy for the development of anxiolytics, with a superior side effect profile to both baclofen and benzodiazepines.

Address correspondence to: Dr. John F. Cryan, Psychiatry Program, Neuroscience Research, The Novartis Institutes for BioMedical Research WSJ 386.344, Novartis Pharma AG, Basel CH-4002, Switzerland. E-mail: john_f.cryan{at}pharma.novartis.com

This article has been cited by other articles:

				N. E. Paterson, S. Vlachou, S. Guery, K. Kaupmann, W. Froestl, and A. Markou Positive Modulation of GABAB Receptors Decreased Nicotine Self-Administration and Counteracted Nicotine-Induced Enhancement of Brain Reward Function in Rats J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 306 - 314. [Abstract] [Full Text] [PDF]

				C. Mombereau, L. Lhuillier, K. Kaupmann, and J. F. Cryan GABAB Receptor-Positive Modulation-Induced Blockade of the Rewarding Properties of Nicotine Is Associated with a Reduction in Nucleus Accumbens {Delta}FosB Accumulation J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 172 - 177. [Abstract] [Full Text] [PDF]

				L. H. Jacobson, B. Bettler, K. Kaupmann, and J. F. Cryan GABAB(1) Receptor Subunit Isoforms Exert a Differential Influence on Baseline but Not GABAB Receptor Agonist-Induced Changes in Mice J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1317 - 1326. [Abstract] [Full Text] [PDF]

				D. S. Dupuis, D. Relkovic, L. Lhuillier, J. Mosbacher, and K. Kaupmann Point Mutations in the Transmembrane Region of GABAB2 Facilitate Activation by the Positive Modulator N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) in the Absence of the GABAB1 Subunit Mol. Pharmacol., December 1, 2006; 70(6): 2027 - 2036. [Abstract] [Full Text] [PDF]

				Y. Chen, N. Menendez-Roche, and E. Sher Differential Modulation by the GABAB Receptor Allosteric Potentiator 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)-phenol (CGP7930) of Synaptic Transmission in the Rat Hippocampal CA1 Area J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1170 - 1177. [Abstract] [Full Text] [PDF]

				D. A. Slattery, S. Desrayaud, and J. F. Cryan GABAB Receptor Antagonist-Mediated Antidepressant-Like Behavior Is Serotonin-Dependent J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 290 - 296. [Abstract] [Full Text] [PDF]

				D. R. Thakker, F. Natt, D. Husken, R. Maier, M. Muller, H. van der Putten, D. Hoyer, and J. F. Cryan Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference PNAS, December 7, 2004; 101(49): 17270 - 17275. [Abstract] [Full Text] [PDF]